Literature DB >> 7505211

Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation.

J G Bender1, K Unverzagt, D E Walker, W Lee, S Smith, S Williams, D E Van Epps.   

Abstract

Single- and multicolor flow cytometry were used to define progenitor subsets in normal human bone marrow and peripheral blood, cord blood, and blood following mobilization of CD34+ progenitor cells by cyclophosphamide or cyclophosphamide/etoposide/G-CSF treatment. CD34 cells were quantitated and subsets of CD34+ cells were defined by coexpression of CD33, CD13, CD10, CD19, CD45RA, and CD71. Myeloid and erythroid progenitors were quantitated by sorting single CD34+ cells into individual wells of 96-well plates containing methylcellulose, IL-3, GM-CSF, G-CSF, IL-6, and erythropoietin. Comparative studies of CD34 cells showed that the percentage of CD34+ mononuclear cells was greatest in blood samples from patients following mobilization treatment with cyclophosphamide/etoposide/G-CSF averaging 2%. By comparison, the remaining sample groups ranged from 1.68 to 0.15% CD34 cells in this order, bone marrow > cord blood > cyclophosphamide mobilized blood > peripheral blood. Comparison of CD34 cells per milliliter of bone marrow or blood showed a range of 22.4 x 10(4) to 0.65 x 10(4)/ml in the following order, bone marrow > chemotherapy/etoposide/G-CSF > cord blood > cyclophosphamide-mobilized blood. Comparative analysis of CD34 subsets from different sources showed significant differences, particularly bone marrow and blood samples. A distinct population of CD34+ CD19+ (Leu 12) CD10+ (CALLA) pre-B lymphocyte cells was defined in bone marrow with lower side and forward light scatter characteristics and was variable between donors (29.8 +/- 16.9%, mean +/- 1 SD; range, 3-54%; n = 8). This population was not found to a significant degree in blood and also expressed CD45RA (Leu 18). Coexpression studies of CD45RA and CD71 (transferrin receptor) expression on CD34+ cells defined a CD45RA- CD71+ population containing 89 +/- 6.3% (n = 4) BFU-E and a CD45RA+ CD71+ population that contained all CFU-GM (n = 4). LeuM7 (CD13) stained a larger percentage to a greater intensity than MY7 (CD13). Coexpression of CD45RA (Leu 18) and CD13 (LeuM7) defined a subset of CD13+ CD45RA+ cells enriched for CFU-GM and CFU-M with a cloning efficiency of 31%. Coexpression of CD33 (MY9) and CD13 (MY7) defined a population that was predominantly CFU-GM with a cloning efficiency of 38%. These studies define CD34+ phenotypes containing pure populations of B lymphocyte, granulocyte-macrophage, or erythroid progenitors and demonstrate the utility of multiparameter flow cytometry to define lineage-committed CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7505211     DOI: 10.1006/clin.1994.1003

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  23 in total

1.  Immunophenotyping of hematopoietic progenitor cells: Comparison between cord blood and adult mobilized blood grafts.

Authors:  Nesrine Ben Azouna; Lamia Berraeis; Zohra Regaya; Faouzi Jenhani
Journal:  World J Stem Cells       Date:  2011-11-26       Impact factor: 5.326

Review 2.  Peripheral blood stem cells: phenotypic diversity and potential clinical applications.

Authors:  Yichi Zhang; Bing Huang
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

3.  The GOD of hematopoietic stem cells: a clonal diversity model of the stem cell compartment.

Authors:  C E Muller-Sieburg; H B Sieburg
Journal:  Cell Cycle       Date:  2006-02-15       Impact factor: 4.534

4.  Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype.

Authors:  Francesca Masiello; Valentina Tirelli; Massimo Sanchez; Emile van den Akker; Girelli Gabriella; Maurizio Marconi; Maria Antonietta Villa; Paolo Rebulla; Ghazala Hashmi; Carolyn Whitsett; Anna Rita Migliaccio
Journal:  Transfusion       Date:  2013-09-04       Impact factor: 3.157

Review 5.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

6.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

7.  Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells.

Authors:  Aditi Bapat; Nakia Keita; Shalini Sharma
Journal:  J Vis Exp       Date:  2019-08-09       Impact factor: 1.355

8.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

9.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 10.  Stem Cells: Potential Therapy for Neonatal Injury?

Authors:  Momoko Yoshimoto; Joyce M Koenig
Journal:  Clin Perinatol       Date:  2015-05-29       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.